You are currently browsing the tag archive for the ‘Gleevec’ tag.

Further to Justice Katju recusing himself from hearing the Novartis Glivec appeal, the Special Leave Petition (SLP) was listed today (11 September) before the Bench consisting of Justice Dalveer Bhandari and Dr. Justice. B.S. Chauhan.

The Supreme Court bench headed by Justice Bhandari issued notices to Centre and all the other parties involved and sought their replies. The respondents include the Ministry of Industry and Commerce, the Controller General of Patent and Design (CGPDTM), the NGO Cancer Patient Aid Association Centre and Pharma companies Natco Pharma, Cipla, Ranbaxy Laboratories and Hetero Drugs.

This SLP is an appeal against the IPAB decision which upheld the Chennai Patent Office decision to refuse the Novartis’ patent application for its cancer drug Gleevec based on Sections 3(d) and 3(b) of the Indian Patent Law.


For those interested in the appeal, a copy of the Special Leave Petition filed by Novartis at the Supreme Court in the Glivec case is available here from the IP Watch website.

Read more from Times Of India here